Irhythm Technologies Inc (IRTC) Will Leave Investors Heartbroken – Kerrisdale

Kerrisdale Capital's short report on Irhythm Technologies Inc (IRTC), titled, "Growth Reversal will Leave Investors Heartbroken."

Q4 hedge fund letters, conference, scoops etc

We are short shares of iRhythm Technologies, a $2.3bn medical device company trading at over 15x sales despite facing multiple factors that will dramatically cut its revenue growth in the coming years. iRhythm’s Zio, developed over a decade ago and . . .


This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email and we will get back to you as quick as humanly possible

Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers